A Novel Bispecific Antibody as an Immunotherapeutic Agent in Hepatocellular Carcinoma

By
lbeveridge
-
0
145
Phase II trials of GC33 to evaluate its efficacy and safety in advanced or metastatic HCC, showed no significant differences in overall survival and progression-free survival compared with the placebo.
[Molecular Immunology]
Abstract